1-3 of 3
Lynn Shaw, RN
Close
Sort by
Journal Articles

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Cristiana A Costa, DO, Bassem I Zaki, MD, Stephanie P Yen, MD, Eric S Winer, MD, Helen Ryan, MD, Darcie Findley, Sara R Metzler, RN, Lynn Shaw, RN, Annie Tsui, RN, Todd A MacKenzie, PhD, Anne W Beaven, MD, Frederick Lansigan, MD
Journal: Blood
Blood (2016) 128 (22): 1793.
https://doi.org/10.1182/blood.V128.22.1793.1793
Published: 2016
Journal Articles

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Results of Fol-Brite

Frederick Lansigan, MD, Bassem I Zaki, MD, Stephanie P Yen, MD, Eric S Winer, MD, Helen Ryan, MD, Darcie L Findley, Sara R Metzler, RN, Lynn Shaw, RN, Annie Tsui, RN, Todd MacKenzie, PhD, Anne W Beaven, MD
Journal: Blood
Blood (2014) 124 (21): 1733.
https://doi.org/10.1182/blood.V124.21.1733.1733
Published: 2014
Journal Articles

Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of “Fol-Brite”

Frederick Lansigan, MD, Eric Winer, MD, Sara R Metzler, RN, Lynn Shaw, RN, Peggy Alton, RN, Kate Foster, MPH, Todd MacKenzie, PhD, Anne W Beaven, MD
Journal: Blood
Blood (2012) 120 (21): 3657.
https://doi.org/10.1182/blood.V120.21.3657.3657
Published: 2012